Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom

Author:

Shi Nianwen1,Durden Emily2,Torres Amelito3,Cao Zhun1,Happich Michael4

Affiliation:

1. Thomson Reuters, Cambridge, MA 02140, USA

2. Thomson Reuters, Washington, DC 20008, USA

3. General Electric Healthcare, 2 Bethesda Metro Center, Bethesda, MD 20814, USA

4. Eli Lilly and Company, Health Technology Appraisal Group, 61352 Bad Homburg, Germany

Abstract

Background.Knowledge about real-world use of duloxetine and venlafaxine XR to treat depression in the UK is limited.Aims.To identify predictors of duloxetine or venlafaxine XR initiation.Method.Adult depressed patients who initiated duloxetine or venlafaxine XR between January 1, 2006 and September 30, 2007 were identified in the UK’s General Practice Research Database. Demographic and clinical predictors of treatment initiation with duloxetine and venlafaxine XR were identified using logistic regression.Results.Patients initiating duloxetine (n=909) were 4 years older than venlafaxine XR recipients (n=1286). Older age, preexisting unexplained pain, respiratory disease, and pre-period use of anticonvulsants, opioids, and antihyperlipidemics were associated with increased odds of initiating duloxetine compared to venlafaxine XR. Pre-period anxiety disorder was associated with decreased odds of receiving duloxetine.Conclusion.Initial treatment choice with duloxetine versus venlafaxine XR was primarily driven by patient-specific mental and medical health characteristics. General practitioners in the UK favor duloxetine over venlafaxine XR when pain conditions coexist with depression.

Funder

Eli Lilly and Company

Publisher

Hindawi Limited

Subject

Psychiatry and Mental health,Clinical Psychology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3